Comparative Pharmacology
Head-to-head clinical analysis: IMODIUM A D EZ CHEWS versus LOPERAMIDE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMODIUM A D EZ CHEWS versus LOPERAMIDE HYDROCHLORIDE.
IMODIUM A-D EZ CHEWS vs LOPERAMIDE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide is a synthetic piperidine derivative that acts directly on intestinal muscle to slow peristalsis, thereby reducing stool frequency and increasing stool consistency. It binds to μ-opioid receptors in the myenteric plexus of the gastrointestinal tract, decreasing acetylcholine release and inhibiting peristalsis. It has minimal central nervous system activity due to poor bioavailability and efflux by P-glycoprotein.
Loperamide binds to µ-opioid receptors in the intestinal wall, reducing propulsive peristalsis and increasing intestinal transit time. It also inhibits calcium-calmodulin-dependent pathways, decreasing electrolyte and water secretion, and enhances anal sphincter tone.
4 mg orally initially, then 2 mg after each unformed stool; maximum 8 mg/day for OTC use (prescription: up to 16 mg/day).
4 mg orally initially, followed by 2 mg after each unformed stool; maximum 16 mg per day. For chronic diarrhea, 4 mg orally once, then 2 mg after each unformed stool until diarrhea controlled; typical maintenance 4-8 mg daily in divided doses. Traveler's diarrhea: 4 mg initially, then 2 mg after each loose stool; maximum 8 mg per day for up to 2 days.
None Documented
None Documented
Terminal elimination half-life is approximately 9–14 hours (mean ~10.8 hours) in healthy adults. In patients with hepatic impairment, half-life may be prolonged.
Terminal elimination half-life is 9-14 hours (mean 10.8 hours) in adults; may be prolonged in hepatic impairment.
Primarily hepatic metabolism with biliary excretion of metabolites; ~1% renal excretion of unchanged drug. Fecal elimination accounts for ~90% of the dose, mainly as conjugated metabolites, with ~1% as unchanged loperamide.
Primarily fecal (30-40% as unchanged drug, 50-60% as metabolites); renal excretion accounts for <5% of unchanged drug and ~10% of metabolites.
Category C
Category A/B
Antidiarrheal
Antidiarrheal